Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2612-2619

  Scialla, Julia J ^a   Leonard, Mary B ^b,c   Townsend, Raymond R ^c   Appel, Lawrence ^a   Wolf, Myles ^d   Budoff, Matt J ^e   Chen, Jing ^f,g   Lustigova, Eva ^g   Gadegbeku, Crystal A ^g   Glenn, Melanie ^b   Hanish, Asaf ^b   RaJ, Dominic ^h   Rosas, Sylvia E ^i,j   Seliger, Stephen L ^i,k   Weir, Matthew R ⁱ   Parekh, Rulan S ^l  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f TULANE UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^k Department of Medicine ^*  (United States)

^l UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; C REACTIVE PROTEIN; CALCIUM; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; SERUM ALBUMIN;

ADULT; AGE DISTRIBUTION; ALBUMINURIA; AORTA; ARTERIAL STIFFNESS; ARTICLE; BLOOD LEVEL; BONE MINERAL; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORTICAL BONE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTIPLE LINEAR REGRESSION ANALYSIS; PHOSPHATE BLOOD LEVEL; PULSE WAVE; QUANTITATIVE ANALYSIS; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TIBIA;

AGED; ANALYSIS OF VARIANCE; AORTA; BIOLOGICAL MARKERS; BONE DENSITY; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PULSATILE FLOW; REGIONAL BLOOD FLOW; RISK ASSESSMENT; RISK FACTORS; TIBIA; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UP-REGULATION;

EID: 80655139707     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03910411     Document Type: Article

References (42)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997
2. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95: 1046-1057, 2004
3. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998
4. Morony S, Tintut Y, Zhang Z, Cattley RC, van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(/) Mice. Circulation 117: 411420, 2008
5. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P: Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110: 536-543, 2007
6. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Development 12: 1260-1268, 1998
7. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ Simonet WS Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192: 463-474, 2000
8. Goodman W, London GM, Amann K, Block GA, Giachelli CM, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N: Vascular calcification in chronic kidney disease. Am J Kidney Dis 43: 572-579, 2004
9. Moe SM, Drueke T: Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 3: S127-S130, 2008
10. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003-1011, 2003
11. Dart AM, Kingwell BA: Pulse pressure-a review of mechanisms and clinical relevance. J Am Coll Cardiol 37: 975-984, 2001
12. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM: Stiffness of capacitive and conduit arteries: Prognostic significance for end-stage renal disease patients. Hypertension 45: 592-596, 2005
13. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. Hypertension 38: 434-438, 2001
14. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47: 1850-1857, 2006
15. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, Hashimoto H, Ikari Y: Serum osteoprotegerin levels and longterm prognosis in subjects with stable coronary artery disease. J Thrombosis Haemostasis 8: 1170-1175, 2010
16. Browner WS, Lui, L-Y, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86: 631-637, 2001
17. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprote-gerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109: 2175-2180, 2004
18. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA: Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 99: 513-518, 2007
19. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA: Plasma osteoprotegerin levels in the general population: Relation to indices of left ventricular structure and function. Hypertension 49: 1392-1398, 2007
20. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJP, Khaw, K-T, Boekholdt SM: Osteoprotegerin and soluble receptor activator of nuclear actor{kappa}B ligand and risk for coronary events: A nested casecontrol approach in the prospective EPIC-Norfolk Population Study 1993-2003. Arterioscler Thromb Vasc Biol 29: 975-980, 2009
21. Nakashima A, Carrero JJ, Qureshi AR, Hirai T, Takasugi N, Ueno T, Taniguchi Y, Lindholm B, Yorioka N: Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int 22: 1695-1701, 2011
22. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory J-P, Maurice F, Delcourt C, Cristol J-P, Canaud B, Dupuy A-M: Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17: 262-270, 2006
23. Sigrist MK, Levin A, Er L, McIntyre CW: Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 24: 3157-3162, 2009
24. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu C-y, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER, III, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 14: S148-S153, 2003
25. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, Lash JP, Chen J, Steigerwalt SP, Flack J, Go AS, Rafey M, Rahman M, Sheridan A, Gadegbeku CA, Robinson NA, Joffe M: Aortic PWV in chronic kidney disease: A CRIC ancillary study. Am J Hypertens 23: 282-289, 2009
26. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003
27. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
28. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439, 1999
29. Nickolas TL, Leonard MB, Shane E: Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74: 721-731, 2008
30. Jamal SA, Gilbert J, Gordon C, Bauer DC: Cortical PQCT measures are associated with fractures in dialysis patients. J Bone Mineral Res 21: 543-548, 2006
31. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr., Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S: Biomarkers of the osteoprotegerin pathway: Clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 30: 1849-1854, 2010
32. Zagura M, Serg M, Kampus P, Zilmer M, Zilmer K, Eha J, Unt E, Lieberg J, Kals, J: Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens 23: 586-591, 2010
33. Helas S, Goettsch C, Schoppet M, Zeitz U, Hempel U, Morawietz H, Kostenuik PJ, Erben RG, Hofbauer LC: Inhibi-tion of receptor activator of NF-{kappa}B ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175: 473-478, 2009
34. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21: 1610-1616, 2001
35. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, LopezOngil S, Coll B, Fernandez E, Valdivielso JM: RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104: 1041-1048, 2009
36. Vitovski S, Phillips JS, Sayers J, Croucher PI: Investigating the interaction between osteoprotegerin and receptor activator of NF-kappa B or tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 282: 31601-31609, 2007
37. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118: 1748-1757, 2008
38. Jono S, Shioi A, Ikari Y, Nishizawa Y: Vascular calcification in chronic kidney disease. J Bone Mineral Metab 24: 176-181, 2006
39. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, Yin X, Rong J, Vita JA, Newton-Cheh C, Levy D, Keaney JF Jr., Vasan RS, Mitchell GF, Benjamin EJ: Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 51: 1651-1657, 2008
40. Frost M, Grella R, Millasseau S, Jiang B-y, Hampson G, Fogelman I, Chowienczyk P: Relationship of calcification of atherosclerotic plaque and arterial stiffness to bone mineral density and osteoprotegerin in postmenopausal women referred for osteoporosis screening. Calcified Tissue Int 83: 112-120, 2008
41. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L: The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23: 3263-3271, 2008
42. Speer G, Fekete BC, El Hadj Othmane T, Szabo T, Egresits J, Fodor E, Kiss I, Logan AG, Nemcsik J, Szabo A, Nemeth ZK, Szathmari M, Tisler A: Serum osteoprotegerin level, carotidfemoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 23: 3256-3262, 2008